{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:30:01Z","timestamp":1782019801195,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Infections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia &amp;lt;0.8 \u00d7 10<jats:sup>9<\/jats:sup>\/L, platelet count &amp;lt;50 \u00d7 10<jats:sup>9<\/jats:sup>\/L, albumin &amp;lt;35g\/L, and ECOG performance status \u22652 has been proposed based on the retrospective data to estimate the risk of infection in azacitidine treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The prospective non-intervention study aimed to identify factors predisposing to infection, validate the AIR score, and assess the impact of antimicrobial prophylaxis on the outcome of azacitidine-treated MDS\/AML and CMML patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We collected data on 307 patients, 57.6 % males, treated with azacitidine: AML (37.8%), MDS (55.0%), and CMML (7.1%). The median age at azacitidine treatment commencement was 71 (range, 18-95) years. 200 (65%) patients were assigned to higher risk AIR group. Antibacterial, antifungal, and antiviral prophylaxis was used in 66.0%, 29.3%, and 25.7% of patients, respectively. In total, 169 infectious episodes (IE) were recorded in 118 (38.4%) patients within the first three azacitidine cycles. In a multivariate analysis ECOG status, RBC transfusion dependency, IPSS-R score, and CRP concentration were statistically significant for infection development (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). The occurrence of infection within the first three azacitidine cycles was significantly higher in the higher risk AIR group \u2013 47.0% than in lower risk 22.4% (odds ratio (OR) 3.06; 95% CI 1.82-5.30, <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Administration of antimicrobial prophylaxis did not have a significant impact on all-infection occurrence in multivariate analysis: antibacterial prophylaxis (OR 0.93; 0.41-2.05, <jats:italic>p<\/jats:italic> = 0.87), antifungal OR 1.24 (0.54-2.85) (<jats:italic>p<\/jats:italic> = 0.59), antiviral OR 1.24 (0.53-2.82) (<jats:italic>p<\/jats:italic> = 0.60).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The AIR Model effectively discriminates infection-risk patients during azacitidine treatment. Antimicrobial prophylaxis does not decrease the infection rate.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1404322","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T04:29:01Z","timestamp":1718252941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["No advantage of antimicrobial prophylaxis in AML\/MDS\/CMML patients treated with azacitidine\u2014a prospective multicenter study by the Polish Adult Leukemia Group"],"prefix":"10.3389","volume":"14","author":[{"given":"Krzysztof","family":"M\u0105dry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Sienkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Biecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktawia","family":"So\u015bnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Go\u0142os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Olszewska-Szopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Walkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"\u015aciesi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Subocz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Machowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Budziszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2016.01.014","article-title":"Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: risk factors and efficacy of antibiotic prophylaxis","volume":"42","author":"Bainschab","year":"2016","journal-title":"Leuk Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.clml.2019.01.002","article-title":"Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: the polish adult leukemia group study","volume":"19","author":"M\u0105dry","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374","article-title":"JOURNAL OF CLINICAL ONCOLOGY antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised.","author":"Swerdlow","year":"2017"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012\u201303-420489.The","article-title":"Revised international prognostic scoring system for MDS","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033506","article-title":"Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome","volume":"96","author":"della Porta","year":"2011","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20132045(09)70003\u20138","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Correspondence","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015\u201301-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040808","article-title":"Infectious complications in patients with myelodysplastic syndromes: A report from the d\u00fcsseldorf MDS registry","volume":"16","author":"Kasprzak","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.clml.2018.05.017","article-title":"Hypomethylating agents-associated infections\u2014Systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Shargian-Alon","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/joh.23368","article-title":"Predicting infections in high-risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine : a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091025.DE","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia Diana","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13077","article-title":"Asymptomatic C-reactive protein elevation in neutropenic children","volume":"59","author":"Sugiura","year":"2017","journal-title":"Pediatr Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S343580","article-title":"The prognostic significance of C-reactive protein to albumin ratio in newly diagnosed acute myeloid leukaemia patients","volume":"14","author":"Dou","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2013017-3001\u20132","article-title":"A retrospective study evaluating the impact of infectious complications during azacitidine treatment","volume":"96","author":"Schuck","year":"2017","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20406207221127547","DOI":"10.1177\/20406207221127547","article-title":"Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD","volume":"13","author":"Vilorio-Marqu\u00e9s","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3091-x","article-title":"The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment","volume":"96","author":"Lorenzana","year":"2017","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.leukres.2010.07.006","article-title":"Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome","volume":"35","author":"Lee","year":"2011","journal-title":"Leuk Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.030","article-title":"Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome","volume":"15","author":"Ofran","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infection"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008226","article-title":"Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB","volume":"7","author":"Clerici","year":"2023","journal-title":"Blood Adv"},{"key":"B24","unstructured":"Epidemiology of Bloodstream Infections in Patients with Acute Myeloid Leukemia Undergoing Levofloxacin Prophylaxis\n            De RosaFG\n            MottaI\n            AudisioE\n          2013"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1404322\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T04:29:05Z","timestamp":1718252945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1404322\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":24,"alternative-id":["10.3389\/fonc.2024.1404322"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1404322","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"article-number":"1404322"}}